Samantha McLemore — Patient Capital ManagementSuperinvestor
About Samantha McLemore — Patient Capital Management’s 13F portfolio
Samantha McLemore — Patient Capital Management is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Samantha McLemore — Patient Capital Management reported $2.7B across 38 US-listed positions (). Its largest position is ROYALTY PHARMA PLC (RPRX) at 6.5% of the reported book, and its ten biggest holdings make up 50% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 |  RPRX ROYALTY PHARMA PLC | $58.73 −0.17% | 6.5% | 3.6M | $174.8M |
| 2 |  C CITIGROUP INC | $133.10 +0.69% | 6.0% | 1.4M | $160.3M |
| 3 |  GOOGL ALPHABET INC | $326.56 +2.13% | 5.7% | 534K | $153.6M |
| 4 |  AMZN AMAZON COM INC | $231.39 −0.31% | 5.1% | 654K | $136.3M |
| 5 |  QXO QXO INC | $14.13 +3.37% | 4.9% | 6.8M | $131.6M |
| 6 |  NVDA NVIDIA CORPORATION | $196.51 −4.99% | 4.6% | 711K | $124.0M |
| 7 |  UNH UNITEDHEALTH GROUP INC | $417.64 −0.74% | 4.4% | 437K | $118.3M |
| 8 |  ET ENERGY TRANSFER L P | $19.91 −2.21% | 4.4% | 6.1M | $117.5M |
| 9 |  IAC IAC INC | $44.54 −4.21% | 4.0% | 2.7M | $108.1M |
| 10 |  NCLH NORWEGIAN CRUISE LINE HLDGS | $20.03 +3.41% | 4.0% | 5.7M | $107.5M |
| 11 |  SDRL SEADRILL LTD | $42.98 −4.34% | 3.7% | 2.2M | $97.9M |
| 12 |  META META PLATFORMS INC | $593.87 −0.22% | 3.6% | 171K | $97.9M |
| 13 |  CVS CVS HEALTH CORP | $107.07 −0.62% | 3.6% | 1.4M | $97.5M |
| 14 |  COIN COINBASE GLOBAL INC | $167.49 +5.81% | 2.8% | 430K | $75.2M |
| 15 |  ADBE ADOBE INC | $237.75 +5.62% | 2.7% | 297K | $72.3M |
| 16 |  CROX CROCS INC | $134.54 −0.13% | 2.6% | 843K | $70.0M |
| 17 |  BIIB BIOGEN INC | $200.14 −0.24% | 2.6% | 380K | $69.6M |
| 18 |  PGEN PRECIGEN INC | $5.42 +0.37% | 2.6% | 17.8M | $69.0M |
| 19 |  UAL UNITED AIRLS HLDGS INC | $120.57 +1.94% | 2.5% | 732K | $67.4M |
| 20 |  ILMN ILLUMINA INC | $189.47 −2.38% | 2.5% | 545K | $67.1M |
| 21 |  NE NOBLE CORP PLC | $43.11 −0.35% | 2.5% | 1.3M | $66.1M |
| 22 |  GM GENERAL MTRS CO | $87.04 +5.32% | 2.1% | 745K | $55.5M |
| 23 |  FISV FISERV INC | $52.31 +2.53% | 2.0% | 968K | $54.0M |
| 24 |  CHYM CHIME FINL INC | $21.86 +5.65% | 2.0% | 2.9M | $54.0M |
| 25 |  UBS UBS GROUP AG | $52.54 +1.55% | 1.8% | 1.2M | $48.5M |
Showing 1–25 of 38 positions on this page reported in this 13F.
Tiles are sized by portfolio weight and coloured by sector; the “est.” figure on each tile is the estimated dividend- and split-adjusted return since the first reported quarter — not the manager’s profit or cost basis.
“Est. return” = estimated dividend/split-adjusted return since the first reported quarter — not the manager’s profit or cost basis.
- Healthcare23%
- Consumer Cyclical17%
- Communication Services14%
- Financial Services13%
- Technology11%
- Energy11%
- Industrials8.8%
- Unclassified2.4%
How this return is calculated
Estimated dividend- and split-adjusted return from the end of the first consecutive reported quarter in which the current holding appears in Bullish Whales’ 13F history, through the manager’s latest reported quarter. Current disclosed holdings only. Start dates differ by holding, changes in position size are not modeled, and positions no longer reported are excluded. Not the manager’s cost basis, purchase date, realized profit or loss, live performance, or portfolio performance.
- AddedRPRXROYALTY PHARMA PLC+9.3%$174.8M
- AddedCCITIGROUP INC+9.5%$160.3M
- AddedAMZNAMAZON COM INC+16.3%$136.3M
- AddedQXOQXO INC+4.8%$131.6M
- AddedNVDANVIDIA CORPORATION+11.3%$124.0M
- AddedUNHUNITEDHEALTH GROUP INC+18.7%$118.3M
- AddedETENERGY TRANSFER L P+15.5%$117.5M
- AddedIACIAC INC+13.7%$108.1M
- AddedNCLHNORWEGIAN CRUISE LINE HLDGS+8.3%$107.5M
- AddedSDRLSEADRILL LTD+4.8%$97.9M
- ReducedGOOGLALPHABET INC−8.2%$153.6M
- ReducedBIIBBIOGEN INC−34.1%$69.6M
- ReducedPGENPRECIGEN INC−4.6%$69.0M
- ReducedILMNILLUMINA INC−5.4%$67.1M
- ReducedGMGENERAL MTRS CO−3.5%$55.5M
- ReducedOMFONEMAIN HLDGS INC−5.3%$41.8M
- ReducedEXPEEXPEDIA GROUP INC−4.8%$38.7M
- ReducedDALDELTA AIR LINES INC−18.8%$36.7M
- ReducedFBTCFIDELITY WISE ORIGIN BITCOIN−54.7%$20.9M
- ReducedPLAYDAVE & BUSTERS ENTMT INC−30.8%$12.5M
Reading Samantha McLemore — Patient Capital Management’s 13F portfolio
Samantha McLemore — Patient Capital Management’s $2.7B 13F book is spread across 38 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 50%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are RPRX, C, GOOGL, AMZN and QXO, led by ROYALTY PHARMA PLC (RPRX) at 6.5% of the portfolio. The heaviest sector exposure is Healthcare (23%), then Consumer Cyclical (17%).
What Samantha McLemore — Patient Capital Management changed last quarter
Between 2025-12-31 and Q1 2026, Samantha McLemore — Patient Capital Management was a net buyer: it opened 2 new positions and added to 23 more, while trimming 11 and closing 4 outright. Against a 38-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ROYALTY PHARMA PLC (RPRX), and its biggest reduction was ALPHABET INC (GOOGL).
What a 13F does and doesn’t reveal
A 13F captures only Samantha McLemore — Patient Capital Management’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Samantha McLemore — Patient Capital Management is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Samantha McLemore — Patient Capital Management's profile on this page is built directly from those filings.
How current is the 13F data on Samantha McLemore — Patient Capital Management's page?
It reflects Samantha McLemore — Patient Capital Management's most recently filed 13F, currently the quarter ending Q1 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Samantha McLemore — Patient Capital Management files its next quarterly report, this page refreshes automatically.
Can I see Samantha McLemore — Patient Capital Management's complete list of holdings?
This page highlights Samantha McLemore — Patient Capital Management's largest positions rather than all 38 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Samantha McLemore — Patient Capital Management's filings.
Does a 13F show everything Samantha McLemore — Patient Capital Management owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Samantha McLemore — Patient Capital Management's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Samantha McLemore — Patient Capital Management made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.